Early Versus Late Ofatumumab (Kesimpta ®) Use in Austrian RMS-Patients Over 2 Years

Condition:   Relapsing Multiple Sclerosis Intervention:   Other: Ofatumumab Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials